Clinical trial · Interventional
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX®) 500 mg With Fulvestrant (FASLODEX®) 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0).
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast cancer treatment and assess the relationship between dose, exposure, degree of reduction in tumor markers, and efficacy in postmenopausal women with estrogen receptor positive disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fulvestrant | Drug | Fulvestrant | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- 250 mg fulvestrant
- interventionNames
- Drug: Fulvestrant
- type
- EXPERIMENTAL
- label
- 2
- description
- 500 mg fulvestrant
- interventionNames
- Drug: Fulvestrant
Primary outcomes (1)
- measure
- Anti-proliferative effect after 4 weeks of treatment.
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Postmenopausal women defined as women who have stopped having menstrual periods * Written informed consent to participate in the trial * Biopsy confirmation of invasive breast cancer * Evidence of hormone sensitivity * Willingness to undergo biopsies Exclusion Criteria: * Any previous treatment for breast cancer * Unwillingness to stop taking any drug known to affect sex hormonal status or a patient in which it would be inappropriate to stop. * Any severe concurrent condition that would preclude surgery or that would jeopardize compliance with the study, e.g., uncontrolled cardiac disease or uncontrolled diabetes mellitus * The presence of more than one primary tumor * History of hypersensitivity to castor oil * History of known bleeding disorders
References
Publications (0)
Data not yet available